OSIRIS THERAPEUTICS, INC.

Delayed Nasdaq  - 
0.000000 USD    0.00%
2019Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc
GL
2019OSIRIS SHAREHOLDER NOTICE : Faruqi & Faruqi, LLP Announces an Investigation of Osiris Therapeutics, Inc. (OSIR) Over the Proposed Merger of the Company with Smith & Nephew plc
PR
2019WeissLaw LLP Investigates Osiris Therapeutics, Inc.
PR
SummaryNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

OSIRIS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces an Investigation of Osiris Therapeutics, Inc. (OSIR) Over the Proposed Merger of the Company with Smith & Nephew plc

03/27/2019 | 02:21pm EDT

NEW YORK, March 27, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating the proposed merger of Osiris Therapeutics, Inc. ("OSIRIS" or the "Company") (NASDAQ:OSIR) with Smith & Nephew plc.

Faruqi & Faruqi, LLP. (PRNewsfoto/Faruqi & Faruqi, LLP)

Click here for more information: www.faruqilaw.com/OSIRIS.  There is no cost or obligation to you.

The firm's investigation focuses on whether Osiris and its Board of Directors violated federal securities laws and/or breached fiduciary duties in relation to the proposed transaction with Smith & Nephew plc., including whether the solicitation material is misleading and whether the merger consideration undervalues the Company to the detriment of Osiris's shareholders.

If you own common stock in Osiris and wish to obtain free of charge additional information about this investigation regarding your investments, please visit us at www.faruqilaw.com/OSIRIS.  You can also contact James M. Wilson, Jr., Esq. either via e-mail at jwilson@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation.  The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation.  The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients. To keep track of the latest securities litigation news, follow us on Twitter at https://twitter.com/faruqilaw  or on Facebook at www.facebook.com/FaruqiLaw.

Contact:
Nadeem Faruqi, Esq.
James M. Wilson, Jr., Esq.
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Telephone: (877) 247-4292 or (212) 983-9330
E-mail: nfaruqi@faruqilaw.com 
jwilson@faruqilaw.com

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.

 

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/osiris-shareholder-notice-faruqi--faruqi-llp-announces-an-investigation-of-osiris-therapeutics-inc-osir-over-the-proposed-merger-of-the-company-with-smith--nephew-plc-300819699.html

SOURCE Faruqi & Faruqi, LLP


© PRNewswire 2019
All news about OSIRIS THERAPEUTICS, INC.
2019Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc
GL
2019OSIRIS SHAREHOLDER NOTICE : Faruqi & Faruqi, LLP Announces an Investigation of Osiris Ther..
PR
2019WeissLaw LLP Investigates Osiris Therapeutics, Inc.
PR
2019Monteverde & Associates PC Announces an Investigation of Osiris Therapeutics, Inc. - OS..
PR
2019ALERT : Rowley Law PLLC is Investigating Proposed Acquisition of Osiris Therapeutics, Inc.
PR
2019OSIRIS THERAPEUTICS, INC. Rigrodsky & Long, P.A. Announces Investigation of Buyout
BU
2019Smith & Nephew to buy Osiris in regenerative products push
RE
2019OSIRIS THERAPEUTICS : Smith & Nephew expands in high growth regenerative medicine market t..
PR
2019Osiris Therapeutics, Inc. Enters Agreement to be Acquired by Smith & Nephew plc
GL
2019HAGENS BERMAN : Notice to Osiris Therapeutics, Inc. Investors: Less than One Week Left to ..
BU
More news